These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 22078241)
1. Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics. Litwin AH; Berg KM; Li X; Hidalgo J; Arnsten JH BMC Infect Dis; 2011 Nov; 11():315. PubMed ID: 22078241 [TBL] [Abstract][Full Text] [Related]
2. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. Bruce RD; Eiserman J; Acosta A; Gote C; Lim JK; Altice FL Am J Drug Alcohol Abuse; 2012 May; 38(3):206-12. PubMed ID: 22242700 [TBL] [Abstract][Full Text] [Related]
3. Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. Akiyama MJ; Agyemang L; Arnsten JH; Heo M; Norton BL; Schackman BR; Linas BP; Litwin AH BMC Infect Dis; 2018 Feb; 18(1):74. PubMed ID: 29426304 [TBL] [Abstract][Full Text] [Related]
4. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Hilsden RJ; Macphail G; Grebely J; Conway B; Lee SS Clin Infect Dis; 2013 Aug; 57 Suppl 2():S90-6. PubMed ID: 23884072 [TBL] [Abstract][Full Text] [Related]
5. Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT). Solomon SS; Sulkowski MS; Amrose P; Srikrishnan AK; McFall AM; Ramasamy B; Kumar MS; Anand S; Thomas DL; Mehta SH J Viral Hepat; 2018 Jan; 25(1):37-46. PubMed ID: 28719029 [TBL] [Abstract][Full Text] [Related]
6. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Taylor LE; Bowman SE; Chapman S; Zaller N; Stein MD; Cioe PA; Maynard MA; McGovern BH Drug Alcohol Depend; 2011 Jul; 116(1-3):233-7. PubMed ID: 21177046 [TBL] [Abstract][Full Text] [Related]
7. Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics. Berg KM; Mouriz J; Li X; Duggan E; Goldberg U; Arnsten JH Contemp Clin Trials; 2009 Sep; 30(5):481-9. PubMed ID: 19505589 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ; Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Bonkovsky HL; Tice AD; Yapp RG; Bodenheimer HC; Monto A; Rossi SJ; Sulkowski MS Am J Gastroenterol; 2008 Nov; 103(11):2757-65. PubMed ID: 18684176 [TBL] [Abstract][Full Text] [Related]
10. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528 [TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112 [TBL] [Abstract][Full Text] [Related]
12. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224 [TBL] [Abstract][Full Text] [Related]
13. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356 [TBL] [Abstract][Full Text] [Related]
14. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225 [TBL] [Abstract][Full Text] [Related]
15. Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics. Nahvi S; Segal KS; Litwin AH; Arnsten JH Addict Sci Clin Pract; 2014 Jun; 9(1):9. PubMed ID: 24928218 [TBL] [Abstract][Full Text] [Related]
16. A comparison of modified directly observed therapy to standard care for chronic hepatitis C. Cioe PA; Stein MD; Promrat K; Friedmann PD J Community Health; 2013 Aug; 38(4):679-84. PubMed ID: 23471655 [TBL] [Abstract][Full Text] [Related]
17. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Grebely J; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Phung N; Weltman MD; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Addiction; 2016 Feb; 111(2):311-9. PubMed ID: 26451534 [TBL] [Abstract][Full Text] [Related]
18. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin. Santantonio T; Fasano M; Sagnelli E; Tundo P; Babudieri S; Fabris P; Toti M; Di Perri G; Marino N; Pizzigallo E; Angarano G; Hepatology; 2014 Jun; 59(6):2101-9. PubMed ID: 24442928 [TBL] [Abstract][Full Text] [Related]
19. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Dore GJ; Hellard M; Matthews GV; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan G; White P; French R; Rawlinson W; Lloyd AR; Kaldor JM; Gastroenterology; 2010 Jan; 138(1):123-35.e1-2. PubMed ID: 19782085 [TBL] [Abstract][Full Text] [Related]